Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Chemical compound from ocean microbe offers potential treatments for anthrax

Chemical compound from ocean microbe offers potential treatments for anthrax

Soligenix announces personalized medicine collaboration with SciClone

Soligenix announces personalized medicine collaboration with SciClone

First clinical study for development of SGX203 to treat pediatric Crohn's disease

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

PharmAthene announces lifting of clinical hold on proposed SparVax Phase II study

PharmAthene announces lifting of clinical hold on proposed SparVax Phase II study

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Pentagon advisor's biotech firm reaps millions for anthrax drug

Pentagon advisor's biotech firm reaps millions for anthrax drug

First Edition: May 20, 2013

First Edition: May 20, 2013

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Glide Pharma awarded contract from Pfenex Inc. to develop a solid formulation of recombinant anthrax vaccine

Glide Pharma awarded contract from Pfenex Inc. to develop a solid formulation of recombinant anthrax vaccine

Scientists demonstrate feasibility of using already-approved drugs against pathogens

Scientists demonstrate feasibility of using already-approved drugs against pathogens

A new method to kill pathogenic bacteria

A new method to kill pathogenic bacteria

New medical device detects biothreat agents

New medical device detects biothreat agents

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

HIV epidemics and extra-couple relationships: an interview with Steve Bellan, University of Texas

HIV epidemics and extra-couple relationships: an interview with Steve Bellan, University of Texas

Washington University creates new type of air-cleaning technology

Washington University creates new type of air-cleaning technology

Positive results from PaxVax's Ad4-H5-Vtn vector vaccine Phase 1 trial on avian flu

Positive results from PaxVax's Ad4-H5-Vtn vector vaccine Phase 1 trial on avian flu

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection